Competitive Treatment in Diffuse Large B-cell lymphoma (DLBCL) and the Future SOC for the First Line Therapy
adding bortezomib was not found to improve DFS and OS significantly. Immunomodulatory agent lenalidomide is another attractive therapeutic option for non-GCB subtype of DLBCL. Statistically significant difference…

